Corrigendum to "Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment" [Neoplasia, Volume 22, Issue 2 (2020) 111-119]
1 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
2 Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
3 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
4 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
5 Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
6 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MIs 48109, USA.
7 Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
8 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MIs 48109, USA. Electronic address: arul@umich.edu.